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 The use of parenteral nutrition (PN) has been the mainstay of treatment for intestinal failure 
(IF) for over 40 years. Until relatively recently the major complications of PN, namely sepsis 
and IF-associated liver disease (IFALD), have been the primary limiters of good long-term 
outcome (1). The multifactorial developments of the last decade have transformed the 
paradigm for patients with long term (Type III) IF, often evidenced by the serial publications 
of the Paris group (2-5). The authors of the article in this issue of JPGN (6) should be 
congratulated on the outcomes described; 98% 10 year survival, in a cohort with a median 
duration of 10 months PN, represents a new aspiration  for professionals looking after these 
children.  However their stratification of patients by diagnostic category and weaning 
prognostic factors sheds new light on the possibilities for patients with ‘potentially 
irreversible IF’ (ultra short segment short bowel syndrome [SBS], neuromuscular disease 
[NMD] and mucosal disorders [MUD]).  
As with previous studies the authors conclude, through multivariate analysis, that SBS 
characteristics (>40cm small bowel, preserved ileocaecal valve and preserved colon ) predict 
enteral weaning, but non-weaning is no longer predictive for death or IFALD. With only one 
death in the cohort, the Paris group now describe equitable survival for NMD and MUD 
despite reduced likelihood of weaning (41% and 14% respectively). This represents a triumph 
for NMD patients, for whom outcomes and quality of life have lagged behind other IF 
diagnoses. Indeed the absolute number and proportion of NMD patients on long-term PN has 
risen considerably in the last two decades (2, 7), but again the authors’ study describes 
equitable outcomes for the first time. These gains may also be secondary to organisation of 
specialist services for complex NMD within supra-regional motility units. With the prospect 
of novel restorative therapies for NMD on the horizon (8), this lends more favour to long 
term PN as a therapy versus small bowel transplantation in such cases. Whilst small bowel 
transplantation continues to have an important role for patients with ‘potentially irreversible 
IF’, the reduction in morbidities and resultant improvement in quality of life demonstrates a 
shrinking proportion of patients requiring intervention despite year-on-year rises in the 
incidence of diseases requiring long-term PN (9).   
What this paper clearly articulates is an expectation for patients with ‘potentially irreversible 
IF’ to spend the majority of time in the community, free from major morbidity and 
particularly IFALD. Their serial publication in this field is also a firm advocate of the role of 
the large specialist service dedicated to all aspects of care of ‘potentially irreversible IF’. The 
evolution of the nutrition support team, led primarily by the paediatric gastroenterology 
multidisciplinary team (MDT), into larger interdepartmental intestinal rehabilitation 
programmes (IRP) has been advocated by many large centres and the transformative effect of 
this is beyond reproach (10). However, despite systematic review, the analyses of the 
individual elements and organisation of the IRP remain elusive in terms of an evidence-based 
appraisal of the contributions of specialist PN/lipid prescribing, sepsis prevention, intestinal 
lengthening surgery, specialist motility expertise and other MDT input (Figure 1). We 
anticipate potential future publication from the Paris group on individual aspects of their care, 
to aide professionals to replicate these outcomes.  
Whilst these data support the further improvements in long term PN, challenges remain for 
patients with poorer outcomes, often minor sub-groups of such study, or those with non 
primary gastrointestinal disorders. Patients with early onset inflammatory and immune-
mediated diseases (including autoimmune enteropathy, classified as non-primary 
gastrointestinal for the purposes of this paper) for example, still report poorer outcomes than 
the IF group as a whole. Further understanding of the pathogenesis and mechanisms of these 
diseases will hopefully lead to more targeted therapies, and the ESPGHAN funded GENIUS 
patient registry is now recruiting to help characterise these diseases(http://www.genius-
group.org/). Additionally as all measures for long term PN improve, the boundaries for such 
therapy will continue to move; mild dysmotility or dysmotility in the context of severe 
neurodisability are conditions that the NST are being asked to manage more frequently. As it 
stands the authors’ paper is a welcome addition to the literature and offers us the future 
agenda for IF, namely the ability to prognosticate for the individual patient and the primary 
focus to move to quality of life rather than just long term survival.  
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Figure Legend 
Figure 1: Shifting the paradigm in intestinal failure over the last decade as evidenced by the 
Paris Group.  
IRP; Intestinal Rehabilitation Programme 
 

